Sarepta reports preclinical SRP‑1003 data showing up to ~80% nuclear DMPK knockdown
Sarepta Therapeutics presented preclinical results for its siRNA candidate SRP‑1003 in myotonic dystrophy type 1 models. The treatment achieved dose‑dependent reductions of pathogenic DMPK mRNA of up to approximately 80% in both nuclear and cytoplasmic compartments. SRP‑1003 remained detectable in multiple muscle groups for up to 16 weeks after a single intravenous dose. The company is running a Phase 1/2 trial and expects to release clinical data later this year.
Why it matters
The data provide functional evidence that SRP‑1003 reaches the nucleus and degrades disease‑causing RNA, strengthening the biological rationale for the program. If clinical results confirm these findings, the candidate could become a first disease‑modifying therapy for DM1, potentially lifting the stock’s valuation.
Key facts
- 1SRP‑1003 reduced pathogenic DMPK mRNA by up to approximately 80% in both nuclear and cytoplasmic compartments in preclinical models. stocktitan.net
- 2The knockdown was dose‑dependent and confirmed by three independent methods (compartment‑fractionated ddPCR, RNA FISH, RNAscope). stocktitan.net
- 3SRP‑1003 remained detectable across multiple muscle groups for up to 16 weeks after a single intravenous dose in preclinical studies. stocktitan.net
- 4The therapy corrected MBNL‑dependent mis‑splicing, providing functional evidence of nuclear activity. investing.com
- 5SRP‑1003 is being evaluated in a first‑in‑human Phase 1/2 trial in DM1 patients aged 18‑65. stocktitan.net
- 6Sarepta expects to share Phase 1/2 trial results later this year. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.